Clinical Trials
25 trialsNCT07556848 2026-04-30
A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 3 Not yet recruiting
NCT07378306 2026-04-21
FACT-TN
Sun Yat-sen University
Phase 2 Recruiting
NCT07078604 2026-04-07
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT07471815 2026-03-13
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
Harbin Medical University
Phase 2 Active not recruiting
NCT07342283 2026-03-02
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
Affiliated Hospital of Nantong University
Phase 2 Recruiting
NCT06627712 2026-01-30
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
West China Hospital
Phase 3 Recruiting
NCT05909332 2026-01-21
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
Fudan University
Phase 3 Recruiting
NCT02806258 2025-12-29
Néo-APBI-01
University Hospital, Grenoble
Phase 1/2 Terminated
NCT06635980 2025-12-12
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Mayo Clinic
Phase 2 Recruiting
NCT05076682 2025-12-03
Renaissance
Fudan University
Phase 2 Recruiting
NCT07161791 2025-09-09
Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer
Harbin Medical University
Phase 1/2 Not yet recruiting
NCT07108309 2025-08-07
AREAL
Biocad
Phase 2 Recruiting
NCT07104266 2025-08-05
Triple Negative Breast Cancer and Celecoxib. Pilot Study
Université de Sherbrooke
Phase 2 Recruiting
NCT07101614 2025-08-03
A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).
Shengjing Hospital
Phase 2 Not yet recruiting
NCT02276443 2025-08-01
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05300958 2025-07-22
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
Sun Yat-sen University
Phase 2 Terminated
NCT06691594 2025-02-20
Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT04638751 2024-04-05
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
Persephone Biosciences
Unknown
NCT04613674 2024-03-27
A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT05999149 2024-02-21
BCTOP-T-N01
Fudan University
Phase 3 Recruiting
NCT05916755 2023-06-23
PORTRAIT
Vall d'Hebron Institute of Oncology
Recruiting
NCT03055312 2021-01-28
SYSUCC-007
Sun Yat-sen University
Phase 3 Terminated
NCT04582955 2020-12-07
Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT02247037 2020-07-07
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
Icahn School of Medicine at Mount Sinai
Completed
NCT02539017 2016-08-10
The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Withdrawn